JP2020505350A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020505350A5 JP2020505350A5 JP2019538484A JP2019538484A JP2020505350A5 JP 2020505350 A5 JP2020505350 A5 JP 2020505350A5 JP 2019538484 A JP2019538484 A JP 2019538484A JP 2019538484 A JP2019538484 A JP 2019538484A JP 2020505350 A5 JP2020505350 A5 JP 2020505350A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- combination according
- acid sequence
- constant region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762448460P | 2017-01-20 | 2017-01-20 | |
| US62/448,460 | 2017-01-20 | ||
| PCT/IB2018/050348 WO2018134782A1 (en) | 2017-01-20 | 2018-01-19 | Combination therapy for the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020505350A JP2020505350A (ja) | 2020-02-20 |
| JP2020505350A5 true JP2020505350A5 (enExample) | 2021-02-25 |
Family
ID=61168137
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019538484A Ceased JP2020505350A (ja) | 2017-01-20 | 2018-01-19 | 癌の治療のための組合せ療法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220356222A9 (enExample) |
| EP (1) | EP3570869A1 (enExample) |
| JP (1) | JP2020505350A (enExample) |
| KR (1) | KR20190105584A (enExample) |
| CN (1) | CN110177568A (enExample) |
| AU (2) | AU2018208883B2 (enExample) |
| CA (1) | CA3046120A1 (enExample) |
| IL (1) | IL266993A (enExample) |
| RU (1) | RU2019122408A (enExample) |
| WO (1) | WO2018134782A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| US20220111008A1 (en) * | 2018-12-13 | 2022-04-14 | Jiangsu Hengrui Medicine Co., Ltd. | Use of il-15 protein complex joint pd-l1 antibody for treating tumor diseases |
| CN116574183A (zh) | 2019-08-22 | 2023-08-11 | 盛禾(中国)生物制药有限公司 | 多功能抗体、其制备及其用途 |
| US20210244821A1 (en) * | 2020-02-05 | 2021-08-12 | Novartis Ag | Cho cell expressed het il-15 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL71691A (en) | 1984-04-27 | 1991-04-15 | Yeda Res & Dev | Production of interferon-ypsilon |
| US6174666B1 (en) | 1992-03-27 | 2001-01-16 | The United States Of America As Represented By The Department Of Health And Human Services | Method of eliminating inhibitory/instability regions from mRNA |
| TW402639B (en) | 1992-12-03 | 2000-08-21 | Transkaryotic Therapies Inc | Protein production and protein delivery |
| US6569681B1 (en) | 2000-03-14 | 2003-05-27 | Transkaryotic Therapies, Inc. | Methods of improving homologous recombination |
| PL1899364T5 (pl) | 2005-05-17 | 2024-12-09 | University Of Connecticut | Kompozycje i sposoby immunomodulacji w organizmie |
| WO2007070488A2 (en) | 2005-12-12 | 2007-06-21 | The Cbr Institute For Biomedical Research, Inc. | Integrin alpha l i domain mutants with increased binding affinity |
| EP1984505B1 (en) | 2006-01-13 | 2019-12-25 | The Government of the U.S.A., as repr. by the Secretary, Dept. of Health & Human Services, the Nat. Inst. of Health | Codon optimized il-15 and il-15r-alpha genes for expression in mammalian cells |
| DK2160401T3 (da) | 2007-05-11 | 2014-10-20 | Altor Bioscience Corp | Fusionsmolekyler og il-15-varianter |
| CN102099221B (zh) | 2008-08-22 | 2014-01-29 | 麦格纳座椅公司 | 具有减小空转的盘形调角器 |
| EP2619229B1 (en) | 2010-09-21 | 2016-04-06 | Altor BioScience Corporation | Multimeric il-15 soluble fusion molecules and methods of making and using same |
| WO2014066527A2 (en) * | 2012-10-24 | 2014-05-01 | Admune Therapeutics Llc | Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes |
| CA2935423C (en) | 2014-01-24 | 2023-11-07 | Dana-Farber Cancer Institute, Inc. | Antibody molecules to pd-1 and uses thereof |
| KR102503476B1 (ko) * | 2014-06-30 | 2023-02-24 | 알토 바이오사이언스 코포레이션 | Il-15-베이즈드 분자 및 이의 사용 방법 |
| WO2016061142A1 (en) * | 2014-10-14 | 2016-04-21 | Novartis Ag | Antibody molecules to pd-l1 and uses thereof |
-
2018
- 2018-01-19 JP JP2019538484A patent/JP2020505350A/ja not_active Ceased
- 2018-01-19 CN CN201880007116.4A patent/CN110177568A/zh active Pending
- 2018-01-19 AU AU2018208883A patent/AU2018208883B2/en not_active Ceased
- 2018-01-19 US US16/479,089 patent/US20220356222A9/en not_active Abandoned
- 2018-01-19 EP EP18703630.6A patent/EP3570869A1/en not_active Withdrawn
- 2018-01-19 WO PCT/IB2018/050348 patent/WO2018134782A1/en not_active Ceased
- 2018-01-19 KR KR1020197020516A patent/KR20190105584A/ko not_active Ceased
- 2018-01-19 CA CA3046120A patent/CA3046120A1/en active Pending
- 2018-01-19 RU RU2019122408A patent/RU2019122408A/ru unknown
-
2019
- 2019-05-29 IL IL266993A patent/IL266993A/en unknown
-
2021
- 2021-05-04 AU AU2021202787A patent/AU2021202787A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023517236A5 (enExample) | ||
| KR102412023B1 (ko) | 레날리도마이드 또는 포말리도마이드 및 ｃｄ38 항체-감쇠 인터페론-알파 구성체의 조합, 및 이의 용도 | |
| JP2024150751A5 (enExample) | ||
| JP2022513420A5 (enExample) | ||
| JP2017529838A5 (enExample) | ||
| RU2017120358A (ru) | Анти-il-1-бета антитела и способы их применения | |
| JP2023542289A5 (enExample) | ||
| JP2023541860A5 (enExample) | ||
| JP2020511947A5 (enExample) | ||
| JP2023542290A5 (enExample) | ||
| JP2014114288A5 (enExample) | ||
| JP2017534646A5 (enExample) | ||
| JP2018522540A5 (enExample) | ||
| JP2023541858A5 (enExample) | ||
| JP2010520290A5 (enExample) | ||
| JP2019517540A5 (enExample) | ||
| JP2023542291A5 (enExample) | ||
| JP2017534645A5 (enExample) | ||
| JP2023542092A5 (enExample) | ||
| CN110612309A (zh) | 用于降低免疫原性的方法和组合物 | |
| JP2020527152A5 (enExample) | ||
| JP2018529661A5 (enExample) | ||
| JP2019532970A5 (enExample) | ||
| TW202104274A (zh) | 用於治療ｈｉｖ感染之三特異性及／或三價結合蛋白 | |
| JP2023510199A5 (enExample) |